Teicoplanin

DB06149

small molecule approved investigational

Deskripsi

Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their ?-D-glucosamine moiety.

Struktur Molekul 2D

Berat 1879.67
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 70-100 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly.

Metabolisme

Two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) have been isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were found to be new teicoplanin-like molecules, bearing 8-hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the omega-2 and omega-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

55 Data
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Teicoplanin.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Teicoplanin.
Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Teicoplanin.
Dicoumarol The risk or severity of bleeding can be increased when Teicoplanin is combined with Dicoumarol.
Phenindione The risk or severity of bleeding can be increased when Teicoplanin is combined with Phenindione.
Warfarin The risk or severity of bleeding can be increased when Teicoplanin is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Teicoplanin is combined with Phenprocoumon.
Acenocoumarol The risk or severity of bleeding can be increased when Teicoplanin is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Teicoplanin is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Teicoplanin is combined with Coumarin.
(R)-warfarin The risk or severity of bleeding can be increased when Teicoplanin is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Teicoplanin is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of bleeding can be increased when Teicoplanin is combined with Fluindione.
Clorindione The risk or severity of bleeding can be increased when Teicoplanin is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Teicoplanin is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Teicoplanin is combined with Tioclomarol.
(S)-Warfarin The risk or severity of bleeding can be increased when Teicoplanin is combined with (S)-Warfarin.
Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Teicoplanin.
Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Teicoplanin.
Estetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Teicoplanin.
Lidocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Quinisocaine.
Cisatracurium Teicoplanin may increase the neuromuscular blocking activities of Cisatracurium.
Ambroxol The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Ambroxol.
Fecal microbiota The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Teicoplanin.

Target Protein

D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan

Referensi & Sumber

Synthesis reference: Emil Toma, Madeleine Ravaoarinoro, "Production and characteristics of anti-teicoplanin polyclonal antibody." U.S. Patent US5612459, issued November, 1990.
Artikel (PubMed)
  • PMID: 1444298
    de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A: Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 1992 Oct;36(10):2192-6.
  • PMID: 1416858
    Bernareggi A, Borghi A, Borgonovi M, Cavenaghi L, Ferrari P, Vekey K, Zanol M, Zerilli LF: Teicoplanin metabolism in humans. Antimicrob Agents Chemother. 1992 Aug;36(8):1744-9.
  • PMID: 17667792
    Yano R, Nakamura T, Tsukamoto H, Igarashi T, Goto N, Wakiya Y, Masada M: Variability in teicoplanin protein binding and its prediction using serum albumin concentrations. Ther Drug Monit. 2007 Aug;29(4):399-403.
  • PMID: 2977108
    Pryka RD, Rodvold KA, Rotschafer JC: Teicoplanin: an investigational glycopeptide antibiotic. Clin Pharm. 1988 Sep;7(9):647-58.
  • PMID: 7791426
    Shea KW, Cunha BA: Teicoplanin. Med Clin North Am. 1995 Jul;79(4):833-44. doi: 10.1016/s0025-7125(16)30042-6.
  • PMID: 2965119
    Greenwood D: Microbiological properties of teicoplanin. J Antimicrob Chemother. 1988 Jan;21 Suppl A:1-13. doi: 10.1093/jac/21.suppl_a.1.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Targocid — Sanofi-Aventis

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul